Impact of Liver Transplantation on Sexual Life and Function

Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years. After the post-operative recovery period, however, LT recipients become more and more confronted with the challenges of re-engagement with life after transplantation, a need to reach a new stability, reestablish function in everyday life, reconnect with valued roles, regain independence, and resume work Sexual function is a very important parameter in the evaluation of Quality of Life (QoL), as it has been shown that sexual dysfunction in transplant patients is associated with increased depression and decreased QoL. There are several studies in the relevant literature supporting the recovery of sexual function in patients after liver transplantation. It has been found that recovery was observed in erectile dysfunction in male patients 6 months after liver transplantation.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years. After the post-operative recovery period, however, LT recipients become more and more confronted with the challenges of re-engagement with life after transplantation, a need to reach a new stability, reestablish function in everyday life, reconnect with valued roles, regain independence, and resume work Sexual function is a very important parameter in the evaluation of Quality of Life (QoL), as it has been shown that sexual dysfunction in transplant patients is associated with increased depression and decreased QoL. There are several studies in the relevant literature supporting the recovery of sexual function in patients after liver transplantation. It has been found that recovery was observed in erectile dysfunction in male patients 6 months after LT

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110070
        • Recruiting
        • ILBS
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Chronic Liver Disease patients awaiting elective transplantation and post liver transplant patients.

Description

Inclusion Criteria:

  1. Married male Patients.
  2. Decompensated Chronic Liver Disease awaiting elective liver transplantation.
  3. Post Liver Transplant patients with stable graft function.

Exclusion Criteria:

  1. Negative consent.
  2. Patients with ongoing medical and surgical issues (biliary complications, graft complication etc.).
  3. Acute on Chronic Liver Failure and Acute Liver Failure patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Chronic liver Disease
Chronic Liver disease patients undergoing elective liver transplantation
This is an Observational Study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of sexual function by questionnaire method
Time Frame: pre transplant, 3,6,12 months
Arizona Sexual Experience Scale (ASEX) scores for sexual dysfunction, ASEX scores are 5 point questionnaire with scores given for each question from 1-6. Total scores More than or equal to 19 indicate sexual dysfunction (higher the scores greater the sexual dysfunction).
pre transplant, 3,6,12 months
Evaluation of erectile dysfunction using questionnaire method
Time Frame: pre transplant, 3,6,12 months
International Index for Erectile Function - 5 (IIEF-5) scores for erectile dysfunction IIEF 5 scores are also a 5 point questionnaire with score ranging 0-6 for each question. Total scores less than 15 indicate mild to moderate erectile dusfunction and scores less than 11 indicate moderate erectile dysfunction (lower the scores higher the erectile dysfunction)
pre transplant, 3,6,12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between testosterone and Meld Na scores
Time Frame: pre transplant, 3,6,12 months
Testosterone measured in ng/ml. Less than 2.84 ng/ml is considered as hypogonadism
pre transplant, 3,6,12 months
Sarcopenia implication in recovery of sexual function.
Time Frame: pre transplant, 3,6,12 months
Sarcopenia measured by third lumbar vertebra Skeletal muscle index. Values less than 52 indicates sarcopenia
pre transplant, 3,6,12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Prof. Dr. Viniyendra Pamecha, MS FEBS, ILBS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 7, 2025

Primary Completion (Estimated)

October 23, 2026

Study Completion (Estimated)

October 23, 2026

Study Registration Dates

First Submitted

November 22, 2025

First Submitted That Met QC Criteria

December 3, 2025

First Posted (Estimated)

December 5, 2025

Study Record Updates

Last Update Posted (Actual)

December 31, 2025

Last Update Submitted That Met QC Criteria

December 24, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • IEC/2024/110/MA03

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Liver Disease and Cirrhosis

Clinical Trials on No Treatment

Subscribe